159 related articles for article (PubMed ID: 16893926)
1. Lapses at the new England journal of medicine.
Smith R
J R Soc Med; 2006 Aug; 99(8):380-2. PubMed ID: 16893926
[No Abstract] [Full Text] [Related]
2. Seeds of doubt--ADVANTAGE no one.
Jackson G
Int J Clin Pract; 2008 Nov; 62(11):1637. PubMed ID: 19143848
[No Abstract] [Full Text] [Related]
3. Response to 'Lapses at the NEJM'.
Drazen JM
J R Soc Med; 2006 Oct; 99(10):485; author reply 485. PubMed ID: 17021294
[No Abstract] [Full Text] [Related]
4. Medical journal criticizes Merck over Vioxx data.
Berenson A
N Y Times Web; 2005 Dec; ():A1, C13. PubMed ID: 16456990
[No Abstract] [Full Text] [Related]
5. How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag".
Armstrong D
Wall St J (East Ed); 2006 May; ():A1, A10. PubMed ID: 16848016
[No Abstract] [Full Text] [Related]
6. NEJM "failed its readers" by delay in publishing its concerns about VIGOR trial.
Dobson R
BMJ; 2006 Jul; 333(7559):116. PubMed ID: 16840463
[No Abstract] [Full Text] [Related]
7. [Overestimated].
Höer A; Häussler B
Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
[No Abstract] [Full Text] [Related]
8. NEJM stands by its criticism of Vioxx study.
Tanne JH
BMJ; 2006 Mar; 332(7540):505. PubMed ID: 16513694
[No Abstract] [Full Text] [Related]
9. Court hears how drug giant Merck tried to "neutralise" and "discredit" doctors critical of Vioxx.
Moynihan R
BMJ; 2009 Apr; 338():b1432. PubMed ID: 19349350
[No Abstract] [Full Text] [Related]
10. Merck's actions surrounding Vioxx.
Heinley M
PLoS Med; 2006 Jun; 3(6):e286; author reply e285. PubMed ID: 16789808
[No Abstract] [Full Text] [Related]
11. NEJM editor gives pretrial evidence in Vioxx case.
Tanne JH
BMJ; 2006 Feb; 332(7536):255. PubMed ID: 16455704
[No Abstract] [Full Text] [Related]
12. 94% of patients suing Merck over rofecoxib agree to company's offer.
Charatan F
BMJ; 2008 Mar; 336(7644):580-1. PubMed ID: 18340064
[No Abstract] [Full Text] [Related]
13. Court awards claimant 13.5m dollars in rofecoxib lawsuit.
Tanne JH
BMJ; 2006 Apr; 332(7547):927. PubMed ID: 16627492
[No Abstract] [Full Text] [Related]
14. Quebec allows Vioxx class-action suit.
Sibbald B
CMAJ; 2007 Jan; 176(1):20. PubMed ID: 17200378
[No Abstract] [Full Text] [Related]
15. Dispute over Vioxx study plays out in New England journal.
Kondro W
CMAJ; 2006 May; 174(10):1397. PubMed ID: 16682702
[No Abstract] [Full Text] [Related]
16. Response to expression of concern regarding VIGOR study.
Reicin A; Shapiro D
N Engl J Med; 2006 Mar; 354(11):1196-9. PubMed ID: 16544387
[No Abstract] [Full Text] [Related]
17. Expression of concern reaffirmed.
Curfman GD; Morrissey S; Drazen JM
N Engl J Med; 2006 Mar; 354(11):1193. PubMed ID: 16495386
[No Abstract] [Full Text] [Related]
18. Response to expression of concern regarding VIGOR study.
Bombardier C; Laine L; Burgos-Vargas R; Davis B; Day R; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien TK; Schnitzer TJ; Weaver A
N Engl J Med; 2006 Mar; 354(11):1196-9. PubMed ID: 16495387
[No Abstract] [Full Text] [Related]
19. The lessons of Vioxx--drug safety and sales.
Waxman HA
N Engl J Med; 2005 Jun; 352(25):2576-8. PubMed ID: 15972862
[No Abstract] [Full Text] [Related]
20. Manipulating a journal article.
N Y Times Web; 2005 Dec; ():WK11. PubMed ID: 16453395
[No Abstract] [Full Text] [Related]
[Next] [New Search]
